Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome

Minimal change disease (MCD) accounts for 15% of adult nephrotic syndrome (NS) cases. Adult-MCD patients may have more severe clinical features than pediatric patients. In children, Rituximab (RTX) has been used since 2006 to treat frequently relapsing NS. In adults, data about the efficacy of RTX f...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Fenoglio, Roberta, Sciascia, Savino, Beltrame, Giulietta, Mesiano, Paola, Ferro, Michela, Quattrocchio, Giacomo, Menegatti, Elisa, Roccatello, Dario
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2018
Gaiak:
Research Paper: Immunology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6034752/
https://ncbi.nlm.nih.gov/pubmed/29989000
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25612
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak